DOST to study mixing Sinovac with other COVID-19 vaccine brands, rollout eyed by June

enablePagination: false
maxItemsPerPage: 10
totalITemsFound:
maxPaginationLinks: 10
maxPossiblePages:
startIndex:
endIndex:

Metro Manila (CNN Philippines, May 24) — The Department of Science and Technology will study how the COVID-19 vaccine made by Chinese firm Sinovac works with other brands, with June as the target start, its chief said on Monday.

In the trial, around 3,000 participants who received Sinovac's CoronaVac will be given another brand to complete their second dose. The study, to be funded by DOST, aims to find the safety and immunogenicity of "mixing-and-matching" different brands.

"Combinations of Sinovac vaccine with other vaccine brand will be the main aim of the study due to it being the most stable vaccine supply in the country," Secretary Fortunato dela Peña said in a statement.

Aside from Sinovac, the Philippines has granted emergency use authorization to AstraZeneca, Sputnik V, Moderna, Pfizer, Covaxin, and single dose Johnson&Johnson.

DOST's trial is slated on June 2021 to November 2022. The official, however, clarified that DOST has yet to receive the go-signal for the study from the Food and Drug Administration and the Philippine Health Research Ethics Board.

The proposed study sites are Antipolo or Marikina City, Manila, Pasig City, Makati or Pasay City, Muntinlupa City, Quezon City, Cebu, and Davao.

There is an ongoing major trial in the United Kingdom to examine whether different coronavirus vaccines can safely be used for two-dose regimens.